Alan Zausner Skarbnik, MD
Hematology · Charlotte, NCNPI 1366754954
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $745,982 of the $1,084,445 with a category attached, or 68.8%. 36 manufacturers reported payments, led by AstraZeneca at 37.1% of the total. Among hematology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 881 payments — averaging $1230.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$402K
- Gilead$132K
- Lilly USA, LLC$96K
- AbbVie$80K
- Beigene USA, Inc.$52K
- ADC Therapeutics America, Inc.$48K
- plus $273K from 30 others
Across 285 payments — averaging $31,320 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$2.5M
- Acerta Pharma LLC$1.7M
- Bristol Myers Squibb$1.5M
- Hoffmann-la Roche Limited$915K
- Genentech, Inc.$729K
- Eli Lilly$588K
- plus $1.1M from 16 others
What the payments were for
- Consulting fees$215,63820%
- Speaking & faculty fees$745,98269%
- Travel & lodging$97,7689%
- Food & beverage$25,0542%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 293 | $402,053 |
| Gilead(2 entities) | 91 | $132,016 |
| Lilly USA, LLC | 68 | $96,500 |
| AbbVie | 78 | $80,162 |
| Beigene USA, Inc. | 30 | $51,966 |
| ADC Therapeutics America, Inc. | 33 | $48,331 |
| Johnson & Johnson | 32 | $43,861 |
| Jazz Pharmaceuticals Inc. | 36 | $39,059 |
| Pharmacyclics LLC, An Abbvie Company | 35 | $30,793 |
| Genentech USA, Inc. | 22 | $26,808 |
| Seagen Inc. | 24 | $23,706 |
| Genmab U.S., Inc. | 31 | $21,007 |
| Bristol Myers Squibb | 23 | $20,101 |
| E.r. Squibb & Sons, L.L.C. | 16 | $17,942 |
| Incyte Corporation | 12 | $12,402 |
| Epizyme, Inc. | 8 | $10,711 |
| Astrazeneca UK Limited | 11 | $9,238 |
| Verastem, Inc. | 7 | $6,928 |
| Kyowa Kirin, Inc. | 1 | $3,900 |
| Novartis | 2 | $1,504 |
| Genentech, Inc. | 2 | $1,351 |
| Morphosys, US Inc. | 2 | $1,338 |
| TG Therapeutics, Inc. | 3 | $652 |
| Secura Bio, Inc. | 5 | $510 |
| Adaptive Biotechnologies Corporation | 4 | $508 |
| Sanofi | 2 | $245 |
| Ipsen Biopharmaceuticals, Inc | 1 | $140 |
| Geron Corporation | 1 | $132 |
| Iovance Biotherapeutics, Inc. | 1 | $126 |
| Pfizer | 1 | $117 |
| Celularity Inc. | 1 | $111 |
| Roche Diagnostics Corporation | 1 | $99 |
| Beone Medicines USA, Inc. | 1 | $54 |
| Legend Biotech USA Inc. | 1 | $37 |
| Acrotech Biopharma Inc. | 1 | $23 |
| Eli Lilly | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,084,445 in reported general payments places this provider in the 95th percentile of 65 hematology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 122 | $1,723,005 |
| RevlimidLenalidomide | 40 | $886,152 |
| BrukinsaZanubrutinib | 64 | $885,794 |
| VenclextaVenetoclax | 31 | $428,884 |
| ValacyclovirValacyclovir Hcl | 118 | $6,358 |
| Entecavir | 29 | $3,907 |
| Fluconazole | 22 | $794 |
| Ondansetron Hcl | 19 | $658 |
| Gabapentin | 28 | $526 |
| Acyclovir | 11 | $486 |
| Potassium Chloride | 28 | $438 |
| Dexamethasone | 13 | $259 |
| Levofloxacin | 25 | $204 |
| Prochlorperazine Maleate | 20 | $200 |
| Pantoprazole Sodium | 15 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $402,053 | $1,723,005122 claims |
| Bristol Myers SquibbRevlimid | $20,101 | $886,15240 claims |
| Beigene USA, Inc.Brukinsa | $51,966 | $885,79464 claims |
| AbbVieVenclexta | $80,162 | $428,88431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 65 hematology providers in North Carolina.
Other hematology in Charlotte
- Ryan JacobsCharlotte$1.5M
- Raymond ThertulienCharlotte$561K
- Ruben MesaCharlotte$384K
- Michael GrunwaldCharlotte$344K
- Nilay ShahCharlotte$228K
- Peter VoorheesCharlotte$157K
- Patricia KropfCharlotte$122K
- Arielle HeekeCharlotte$88K
- Earle BurgessCharlotte$75K
- Omotayo FasanCharlotte$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.